Trial Profile

A Retrospective Study to Investigate the Effect of Bupivacaine Liposomal Injectable Suspension (BLIS) on Opioid Use, Hospital Length of Stay, Discharge Status and Hospitalization Costs in Patients Undergoing Total Hip Arthroplasty (THA) at High Use Hospitals

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jun 2019 Primary endpoint (Home discharge status: BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
12 Jun 2019 Primary endpoint (Hospital length of stay (LOS): BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
12 Jun 2019 According to a Pacira BioSciences media release, new data from this study were published in The Journal of Medical Economics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com